Cellectar Biosciences, Inc.

Company Listings from SPi: Cellectar Biosciences, Inc.

You are here: Home >> SPi Company Listings >> Cellectar Biosciences, Inc.

 

Cellectar Biosciences, Inc.

Website:
http://

Search for other references to "cellectar" on SPi News

Latest Cellectar Biosciences, Inc. News

Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma FLORHAM PARK, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and c...... 13:30 GMT Monday 7th January 2019

Cellectar Biosciences to Present at the Biotech Showcase FLORHAM PARK, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development...... 13:30 GMT Thursday 3rd January 2019

Cellectar Granted Japanese Patent for CLR 131 FLORHAM PARK, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development...... 13:30 GMT Tuesday 11th December 2018

Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma FLORHAM PARK, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and c...... 13:30 GMT Tuesday 4th December 2018

Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update FLORHAM PARK, N.J., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical compan...... 13:30 GMT Tuesday 13th November 2018

Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies FLORHAM PARK, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development...... 13:30 GMT Monday 12th November 2018

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma MADISON, Wis., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commer...... 13:00 GMT Tuesday 2nd October 2018

Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference MADISON, Wis., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...... 13:30 GMT Thursday 27th September 2018

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma MADISON, Wis., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...... 13:30 GMT Tuesday 25th September 2018

Cellectar Biosciences Provides an Update on the FDA Import Alert MADISON, Wis., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...... 13:00 GMT Monday 24th September 2018

Buy Cellectar Biosciences, Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us